

Kyowa Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2022 Interim

(January 1, 2022 - June 30, 2022)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on August 4, 2022 for the first six months of Fiscal 2022, from January 1, 2022 to June 30, 2022.
- This document is an English translation of the Japanese-language original. The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- "FY 2022 forecasts" in these materials have been revised from the forecasts released on February 7, 2022.
- Figures presented in these materials have been rounded to the nearest tenth.
- Figures inside parenthesis presented in these materials indicate negative values.

Index	Page
I . Consolidated Financial Results	
1. Trends in consolidated profit	1
2. Revenue by regional control function	2
3. Revenue by location of customer	2
4. Capital expenditures (property, plant and equipment) and intangible assets investment	2
5. Depreciation and amortization	2
II . Consolidated Statement of Cash Flows	2
III . Revenue from Main Products	3
IV . R&D Pipeline	6

The average exchange rates for each period were as follows:

Unit: Yen

	FY 2021 results				FY 2022 results		FY 2022 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Dec
USD	105	107	108	109	114	120	128
GBP	143	147	149	150	154	158	162
CNY	16.1	16.4	16.6	16.9	18.0	18.7	19.4

<p>Contact Kyowa Kirin Co., Ltd. Corporate Communications Department Tel +81 3 5205 7206</p>

I . Consolidated Financial Results
1. Trends in consolidated profit
 <Accumulative>

The "★" symbol indicates financial KPIs (numerical guidance) that were set as targets in the FY2021-2025 Medium Term Business Plan.

Unit: Billions of yen

	FY 2021 results				FY 2022 results				FY 2022 forecasts		FY2021-2025 Medium Term Business Plan Financial KPIs
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Change amount	Rate of change	Jan - Dec	Progress	
Revenue	81.1	165.0	254.0	352.2	87.8	185.3	20.2	12%	400.0	46%	
★ CAGR (compared to FY 2020)	-	-	-	10.6%	-	-	-	-	12.1%	-	10% or higher
Cost of sales	(22.4)	(41.2)	(64.1)	(87.8)	(22.2)	(43.4)	(2.1)	5%	(88.0)	49%	
Gross profit	58.7	123.8	189.9	264.4	65.6	141.9	18.1	15%	312.0	45%	
Gross profit to revenue ratio	72.4%	75.0%	74.8%	75.1%	74.7%	76.6%	-	-	78.0%	-	
Selling, general and administrative expenses	(31.7)	(67.2)	(104.1)	(145.6)	(36.1)	(76.4)	(9.2)	14%	(172.0)	44%	
Research and development expenses	(12.2)	(26.5)	(40.2)	(57.7)	(13.6)	(27.9)	(1.4)	5%	(67.0)	42%	
★ R&D expense ratio	15.0%	16.1%	15.8%	16.4%	15.5%	15.1%	-	-	16.8%	-	Target of 18-20%
Share of profit (loss) of investments accounted for using equity method	0.6	0.9	1.3	4.6	1.4	2.4	1.5	158%	4.0	59%	
Core operating profit	15.5	30.9	46.8	65.7	17.3	39.9	9.0	29%	77.0	52%	
★ Core operating profit ratio	19.1%	18.8%	18.4%	18.6%	19.8%	21.5%	-	-	19.3%	-	25% or higher
Other income	0.2	0.4	0.7	1.0	0.4	0.6	0.2	60%			
Other expenses	(0.2)	(1.1)	(5.8)	(6.6)	(0.2)	(1.2)	(0.1)	14%			
Finance income (costs)	0.6	0.9	0.1	(0.0)	1.2	4.2	3.4	386%			
Profit before tax	16.2	31.1	41.9	60.1	18.7	43.5	12.4	40%	79.0	55%	
Income tax expense	(3.2)	(6.0)	(9.0)	(7.7)	(2.7)	(8.5)	(2.4)	40%	(16.0)	53%	
Ratio of income tax burden	20.0%	19.4%	21.4%	12.8%	14.3%	19.5%	-	-	20.3%	-	
Profit	12.9	25.1	32.9	52.3	16.0	35.0	9.9	40%	63.0	56%	
Profit to revenue ratio	15.9%	15.2%	13.0%	14.9%	18.3%	18.9%	-	-	15.8%	-	

EPS (¥/share)	24.05	46.67	61.25	97.43	29.85	65.16	18.49	-	117.22	-
Core EPS (¥/share) ¹	24.00	47.75	68.62	106.57	29.52	66.14	18.39	-	118.71	-
Annual dividend (¥/share)				46.00					48.00	-
★ Dividend payout ratio (%) ²				43.2					40.4	-
★ ROE (%)				7.3					8.3	-

¹ Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting "other income," "other expenses" and the related "income tax expense" from "profit") by the average number of shares during the period.

² Dividend payout ratio is shown based on core EPS.

<Quarterly>

Unit: Billions of yen

	FY 2021 results				FY 2022 results			
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Change amount	Rate of change
Revenue	81.1	83.9	88.9	98.3	87.8	97.5	13.6	16%
Cost of sales	(22.4)	(18.9)	(22.9)	(23.7)	(22.2)	(21.2)	(2.4)	13%
Gross profit	58.7	65.0	66.1	74.5	65.6	76.3	11.2	17%
Gross profit to revenue ratio	72.4%	77.5%	74.3%	75.8%	74.7%	78.2%	-	-
Selling, general and administrative expenses	(31.7)	(35.6)	(36.9)	(41.5)	(36.1)	(40.4)	(4.8)	13%
Research and development expenses	(12.2)	(14.3)	(13.7)	(17.4)	(13.6)	(14.3)	0.0	(0)%
★ R&D expense ratio	15.0%	17.0%	15.4%	17.8%	15.5%	14.7%	-	-
Share of profit (loss) of investments accounted for using equity method	0.6	0.3	0.4	3.3	1.4	0.9	0.7	231%
Core operating profit	15.5	15.4	15.9	18.9	17.3	22.6	7.1	46%
★ Core operating profit ratio	19.1%	18.4%	17.8%	19.2%	19.8%	23.1%	-	-
Other income	0.2	0.1	0.4	0.2	0.4	0.2	0.0	8%
Other expenses	(0.2)	(0.9)	(4.7)	(0.8)	(0.2)	(1.0)	(0.1)	14%
Finance income (costs)	0.6	0.3	(0.8)	(0.1)	1.2	3.1	2.8	1077%
Profit before tax	16.2	14.9	10.8	18.2	18.7	24.8	9.8	66%
Income tax expense	(3.2)	(2.8)	(3.0)	1.3	(2.7)	(5.8)	(3.0)	107%
Profit	12.9	12.2	7.8	19.4	16.0	19.0	6.8	56%
Profit to revenue ratio	15.9%	14.5%	8.8%	19.8%	18.3%	19.5%	-	-

2. Revenue by regional control function

Unit: Billions of yen

	FY 2021 results				FY 2022 results			FY 2022 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Change amount	Jan - Dec	Progress
Japan	39.2	76.7	114.9	156.9	35.4	72.8	(3.9)	148.4	49%
North America	15.9	34.6	54.2	78.8	20.7	47.5	12.9	112.5	42%
EMEA	12.0	25.9	39.8	56.1	14.5	30.9	5.0	66.2	47%
Asia/Oceania	6.9	14.3	22.1	28.4	7.2	14.8	0.5	30.6	48%
Others	7.1	13.6	23.0	32.1	9.8	19.3	5.7	42.3	46%
Total consolidated revenue	81.1	165.0	254.0	352.2	87.8	185.3	20.2	400.0	46%

* Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin structure (a global management structure with axes combining four regions – Japan, North America, EMEA, and Asia/Oceania – and the functions needed by a global specialty pharmaceutical company).

* EMEA consists of Europe, the Middle East, Africa, etc.

* Others consists of revenue from technology out-licensing, original equipment manufacturing, etc.

3. Revenue by location of customer

Unit: Billions of yen

	FY 2021 results					FY 2022 results			FY 2022 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Percentage of consolidated revenue	Jan - Mar	Jan - Jun	Percentage of consolidated revenue	Jan - Dec	Percentage of consolidated revenue
Japan	40.9	79.9	119.1	162.0	46%	36.9	75.8	41%	154.0	38%
International	40.3	85.1	134.9	190.3	54%	50.9	109.5	59%	246.0	62%
Americas	20.6	43.4	69.9	102.2	29%	28.2	62.2	34%	146.5	37%
Of which, the U.S.	20.0	41.7	67.9	99.3	28%	27.3	60.3	33%		
Europe	11.3	24.4	38.2	53.4	15%	13.5	28.8	16%	64.5	16%
Asia	8.2	17.1	26.7	34.5	10%	9.1	18.4	10%	35.0	9%
Others	0.0	0.1	0.1	0.2	0%	0.0	0.1	0%	0.0	0%
Total consolidated revenue	81.1	165.0	254.0	352.2	100%	87.8	185.3	100%	400.0	100%

* Revenue by location of customer is classified by region or country based on location of customer.

4. Capital expenditures (property, plant and equipment) and intangible assets investment

Unit: Billions of yen

	FY 2021 results				FY 2022 results		FY 2022 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Dec
Capital expenditures (property, plant and equipment)	2.0	2.8	4.7	9.1	1.8	5.0	18.3
Intangible assets investment	1.6	2.9	11.1	13.2	1.0	3.1	11.7
Total	3.7	5.7	15.8	22.3	2.8	8.2	30.0

* Acquisitions of right-of-use assets are not included.

5. Depreciation and amortization

Unit: Billions of yen

	FY 2021 results				FY 2022 results		FY 2022 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Dec
Depreciation (property, plant and equipment)	2.8	5.5	8.3	11.2	2.9	6.0	12.1
Amortization (intangible assets)	1.9	3.7	5.6	8.3	1.7	3.5	7.0
Total	4.6	9.2	13.9	19.5	4.6	9.5	19.0

II. Consolidated Statement of Cash Flows

Unit: Billions of yen

	FY 2021 results				FY 2022 results		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Change amount
Cash flows from operating activities	14.4	23.0	81.2	86.5	8.8	22.5	(0.6)
Cash flows from investing activities	(4.6)	(1.9)	(10.8)	(11.4)	(4.6)	(6.8)	(5.0)
Cash flows from financing activities	(13.5)	(14.3)	(27.6)	(28.4)	(13.2)	(14.1)	0.2
Effect of exchange rate changes on cash and cash equivalents	0.4	(1.1)	0.6	1.3	0.4	3.3	4.4
Net increase (decrease) in cash and cash equivalents	(3.3)	5.7	43.4	48.1	(8.6)	4.8	(0.9)
Cash and cash equivalents at beginning of period	287.0	287.0	287.0	287.0	335.1	335.1	48.1
Cash and cash equivalents at end of period	283.8	292.8	330.4	335.1	326.5	339.9	47.1

III. Revenue from Main Products

<Accumulative>

Unit: Billions of yen

Product name		FY 2021 results				FY 2022 results			FY 2022 forecasts	
		Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Change amount	Jan - Dec	Progress
Japan	Nesp	1.0	1.9	2.9	4.0	0.8	1.6	(0.3)	3.3	50%
	Darbepoetin Alfa Injection Syringe [KKF]	5.5	11.0	16.7	22.3	4.4	8.8	(2.2)	17.4	51%
	Duvroq	0.2	0.5	1.4	2.6	1.1	2.7	2.1	5.9	46%
	Regpara	0.7	1.5	2.1	2.9	0.5	1.1	(0.3)	2.0	56%
	Orkedia	2.1	4.6	7.1	9.9	2.2	4.9	0.3	10.4	47%
	Rocaltrol	0.7	1.5	2.3	3.2	0.7	1.5	(0.0)	3.1	50%
	Onglyza	1.5	3.0	4.6	6.2	1.2	2.6	(0.5)	5.1	50%
	Coniel	0.6	1.3	2.0	2.7	0.6	1.1	(0.2)	2.0	56%
	G-Lasta	6.6	13.8	21.2	29.4	7.1	14.8	1.0	31.5	47%
	Fentos	0.8	1.8	2.8	3.9	0.8	1.8	(0.0)	3.7	48%
	Poteligeo	0.5	0.9	1.5	2.0	0.5	1.0	0.0	2.0	49%
	Rituximab BS [KHK]	2.6	5.3	8.1	11.2	2.5	5.0	(0.2)	10.3	49%
	Romiplate	1.5	2.8	4.9	7.3	2.2	4.8	1.9	10.0	48%
	Allelock	2.9	4.8	6.3	8.0	2.4	3.8	(1.0)	5.6	69%
	Patanol	6.5	7.8	9.2	10.7	1.8	2.2	(5.6)	3.0	72%
	Dovobet	1.5	3.5	5.2	7.2	1.7	3.8	0.3	7.7	49%
	Lumicef	0.6	1.4	2.1	2.9	0.7	1.5	0.1	3.1	48%
	Nourias	1.9	4.2	6.4	8.7	1.8	3.9	(0.3)	8.1	48%
	HARUROPI	0.6	1.3	2.2	3.1	0.8	1.8	0.4	4.1	43%
	Depakene	0.8	1.7	2.7	3.6	0.8	1.7	(0.0)	3.5	48%
Crysvita	1.5	3.3	5.1	7.2	2.0	4.1	0.8	9.2	45%	
Technology out-licensing	0.6	1.3	1.5	1.6	0.1	0.4	(0.9)	0.9	43%	
International	Crysvita	16.3	35.4	55.1	78.3	22.2	49.4	14.0	116.2	43%
	Poteligeo	3.2	7.0	11.0	15.3	4.2	10.3	3.3	23.6	44%
	Nouriaz	1.0	1.9	3.1	4.5	1.1	2.6	0.7	6.1	42%
	Abstral	1.8	4.0	6.3	8.5	1.4	3.6	(0.4)	7.2	50%
	Pecfent	1.0	1.9	2.9	3.9	1.0	1.7	(0.3)	3.6	47%
	Moventig	0.6	1.4	2.0	2.8	0.7	1.5	0.1	3.4	43%
	Adcal-D3	0.6	1.3	2.1	3.0	0.7	1.5	0.2	2.9	52%
	Nesp	1.6	3.2	4.9	6.4	1.9	3.9	0.7	7.6	51%
	Regpara	2.2	4.6	6.7	7.4	1.0	2.0	(2.6)	3.8	52%
	Neulasta/Peglata	1.3	2.6	4.0	5.3	1.7	3.0	0.4	6.0	49%
	Gran	1.3	3.0	4.9	6.3	2.1	3.8	0.8	7.9	49%
	Technology out-licensing	4.9	9.1	16.4	24.5	7.7	15.3	6.2	35.0	44%
	Of which, Benralizumab royalty	3.8	7.1	11.7	16.8	4.7	9.3	2.1		

* Revenue from products is classified as Japan or International (other than Japan) based on consolidated revenue from regional control functions and technology out-licensing is classified as Japan or International (other than Japan) based on the location of the customer.

* Revenue from main products does not include revenue from the Early Access Program (EAP).

* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

III. Revenue from Main Products

<Quarterly>

Unit: Billions of yen

Product name		FY 2021 results				FY 2022 results		
		Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Change amount
Japan	Nesp	1.0	1.0	1.0	1.1	0.8	0.8	(0.1)
	Darbepoetin Alfa Injection Syringe [KKF]	5.5	5.5	5.6	5.6	4.4	4.4	(1.1)
	Duvroq	0.2	0.4	0.8	1.2	1.1	1.6	1.2
	Regpara	0.7	0.8	0.7	0.7	0.5	0.6	(0.2)
	Orkedia	2.1	2.5	2.5	2.7	2.2	2.7	0.2
	Rocaltrol	0.7	0.8	0.8	0.9	0.7	0.8	(0.0)
	Onglyza	1.5	1.6	1.5	1.6	1.2	1.3	(0.2)
	Coniel	0.6	0.7	0.7	0.7	0.6	0.5	(0.2)
	G-Lasta	6.6	7.2	7.4	8.2	7.1	7.7	0.5
	Fentos	0.8	1.0	1.0	1.0	0.8	1.0	(0.0)
	Poteligeo	0.5	0.5	0.5	0.5	0.5	0.5	0.0
	Rituximab BS [KHK]	2.6	2.7	2.8	3.1	2.5	2.5	(0.1)
	Romiplate	1.5	1.3	2.1	2.4	2.2	2.6	1.3
	Allelock	2.9	1.9	1.4	1.8	2.4	1.4	(0.5)
	Patanol	6.5	1.2	1.5	1.5	1.8	0.3	(0.9)
	Dovobet	1.5	2.0	1.7	2.0	1.7	2.1	0.1
	Lumicef	0.6	0.7	0.7	0.8	0.7	0.8	0.0
	Nourias	1.9	2.3	2.2	2.3	1.8	2.1	(0.2)
	HARUROPI	0.6	0.8	0.8	1.0	0.8	1.0	0.2
	Depakene	0.8	0.9	1.0	0.9	0.8	0.8	(0.1)
Crysvita	1.5	1.9	1.8	2.1	2.0	2.2	0.3	
Technology out-licensing	0.6	0.7	0.1	0.2	0.1	0.3	(0.4)	
International	Crysvita	16.3	19.2	19.6	23.3	22.2	27.2	8.0
	Poteligeo	3.2	3.8	4.0	4.3	4.2	6.1	2.2
	Nourianz	1.0	1.0	1.1	1.5	1.1	1.4	0.5
	Abstral	1.8	2.2	2.2	2.3	1.4	2.2	(0.0)
	Pecfent	1.0	0.9	1.0	1.0	1.0	0.7	(0.3)
	Moventig	0.6	0.8	0.7	0.8	0.7	0.8	(0.1)
	Adcal-D3	0.6	0.7	0.8	0.9	0.7	0.8	0.2
	Nesp	1.6	1.6	1.7	1.5	1.9	2.0	0.4
	Regpara	2.2	2.3	2.2	0.7	1.0	1.0	(1.3)
	Neulasta/Peglata	1.3	1.3	1.4	1.3	1.7	1.3	0.0
	Gran	1.3	1.7	1.9	1.4	2.1	1.8	0.0
	Technology out-licensing	4.9	4.1	7.3	8.0	7.7	7.6	3.5
Of which, Benralizumab royalty	3.8	3.4	4.6	5.1	4.7	4.6	1.2	

* Revenue from products is classified as Japan or International (other than Japan) based on consolidated revenue from regional control functions and technology out-licensing is classified as Japan or International (other than Japan) based on the location of the customer.

* Revenue from main products does not include revenue from the Early Access Program (EAP).

* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

III. Revenue from Main Products

Revenue of three global strategic products

<Accumulative>

Unit: Billions of yen

Product name	FY 2021 results				FY 2022 results			FY 2022 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Change amount	Jan - Dec	Progress
Crysvita	17.8	38.8	60.2	85.5	24.2	53.5	14.8	125.4	43%
Japan	1.5	3.3	5.1	7.2	2.0	4.1	0.8	9.2	45%
North America	11.7	25.7	40.3	57.7	15.8	35.9	10.1		
EMEA	4.5	9.7	14.8	20.6	6.3	13.5	3.8	116.2	43%
Asia/Oceania	-	-	0.0	0.0	0.0	0.1	0.1		
Poteligeo	3.6	7.9	12.4	17.3	4.7	11.3	3.3	25.6	44%
Japan	0.5	0.9	1.5	2.0	0.5	1.0	0.0	2.0	49%
North America	2.6	5.8	9.2	12.7	3.3	8.1	2.3	18.1	45%
EMEA	0.6	1.1	1.8	2.6	0.9	2.1	1.0	5.5	39%
Nourias/Nourianz	2.9	6.1	9.4	13.2	2.9	6.5	0.3	14.2	45%
Japan	1.9	4.2	6.4	8.7	1.8	3.9	(0.3)	8.1	48%
North America	1.0	1.9	3.1	4.5	1.1	2.6	0.7	6.1	42%
Total of three global strategic products	24.2	52.8	82.0	116.0	31.8	71.3	18.5	165.2	43%

<Quarterly>

Unit: Billions of yen

Product name	FY 2021 results				FY 2022 results		
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Change amount
Crysvita	17.8	21.0	21.4	25.3	24.2	29.4	8.4
Japan	1.5	1.9	1.8	2.1	2.0	2.2	0.3
North America	11.7	14.0	14.5	17.5	15.8	20.0	6.0
EMEA	4.5	5.2	5.1	5.8	6.3	7.1	2.0
Asia/Oceania	-	-	0.0	0.0	0.0	0.0	0.0
Poteligeo	3.6	4.3	4.5	4.9	4.7	6.6	2.3
Japan	0.5	0.5	0.5	0.5	0.5	0.5	0.0
North America	2.6	3.2	3.3	3.5	3.3	4.8	1.6
EMEA	0.6	0.6	0.6	0.8	0.9	1.2	0.6
Nourias/Nourianz	2.9	3.3	3.3	3.8	2.9	3.6	0.3
Japan	1.9	2.3	2.2	2.3	1.8	2.1	(0.2)
North America	1.0	1.0	1.1	1.5	1.1	1.4	0.5
Total of three global strategic products	24.2	28.6	29.2	34.0	31.8	39.5	10.9

* Revenue is classified based on consolidated revenue from regional control functions.

* Revenue from main products does not include revenue from the Early Access Program (EAP).

IV. R&D Pipeline

© New Molecular Entity
 Updated since Dec. 31, 2021
 Updated since Mar. 31, 2022

Nephrology

antibody protein small molecule

As of Jun. 30, 2022

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN Asia						[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia
© RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Alport Syndrome	JP						[Reata]
		Diabetic Kidney Disease	JP						
		Autosomal Dominant Polycystic Kidney Disease	JP						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House] product name in Japan: Acoalan
KHK7791 Tenapanor Hydrochloride Oral	NHE3 Inhibitor	Hyperphosphatemia in Patients on Dialysis	JP						[Ardelyx]

Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	CA						[In-House] POTELLIGENT® product name in Japan, U.S. and Europe: Poteligeo
			AE IL						
			CN KR KW						
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony- Stimulating Factor	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation	JP						[Amgen K-A] product name in Japan: G-Lasta
		Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation	JP						
		Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP						
©ME-401 Zandelisib Oral	PI3Kδ Inhibitor	Follicular Lymphoma and Marginal Zone Lymphoma	JP NA Europe Asia Oceania others						[MEI Pharma] Combination with rituximab Second line +
		Follicular Lymphoma	NA Europe Asia Oceania						[MEI Pharma] Third line +
		Marginal Zone Lymphoma	NA Europe Asia Oceania						[MEI Pharma] Third line +
		Indolent B-cell Non-Hodgkin's Lymphoma	JP						[MEI Pharma] Third line +
		B-cell malignancies	NA						[MEI Pharma] Monotherapy, combination with rituximab and combination with zanubrutinib

※ Since the development of KHK2455 for solid tumor and urothelial carcinoma was discontinued, the relevant information was deleted from this table.

Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Ankylosing Spondylitis	TW						[Amgen K-A] product name in Japan: Lumicef
		Ankylosing Spondylitis	MY TH						
		Non-radiographic Axial Spondyloarthritis	TH						
		Systemic Sclerosis	JP						
		Palmoplantar Pustulosis	JP						
©KHK4083/AMG 451 Rocatinlimab Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP NA Europe						[In-House] POTELLIGENT® Human Antibody-Producing Technology Collaboration agreement with Amgen for the development of KHK4083/AMG 451 in all the countries except for Japan.

IV. R&D Pipeline

antibody
 protein
 small molecule

© New Molecular Entity
 Updated since Dec. 31, 2021
 Updated since Mar. 31, 2022

Central Nervous System

As of Jun. 30, 2022

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist/Inverse Agonist	Parkinson's Disease	JP						[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP Europe						[Immunas Pharma]

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	TH						[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU product name in Japan, U.S. and Europe: Crystvita
		Tumor Induced Osteomalacia (TIO)	MY						
			Europe						
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP) Who Do Not Respond Well to Other Treatments, Such as Corticosteroids and Immunoglobulin	CN						[Amgen K-A] product name in Japan: Romiplate
		Treatment of Aplastic Anemia (AA) Which Is Refractory to Immunosuppressive Therapy or AA not Amenable to Immunosuppressive Therapy	SG						
		Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	MY TH						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	JP Asia						[In-House] product name in Japan: Acoalan
KHK4951 Ophthalmic		Wet Age-Related Macular Degeneration	JP						[In-House]

※ We decided to discontinue the development of KW-6356 in the central nervous system field in July.